Palvella Therapeutics, Inc.
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2015-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.palvellatx.com
A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Cutaneous Venous Malformations
- Conditions
- Cutaneous Venous Malformations
- Interventions
- First Posted Date
- 2024-10-22
- Last Posted Date
- 2025-03-28
- Lead Sponsor
- Palvella Therapeutics, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT06653842
- Locations
- 🇺🇸
Children's Hospital of Orange County, Irvine, California, United States
🇺🇸Colorado Children's Hospital, Aurora, Colorado, United States
🇺🇸John's Hopkins, Baltimore, Maryland, United States
SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations
- Conditions
- Microcystic Lymphatic Malformation
- Interventions
- First Posted Date
- 2024-02-02
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- Palvella Therapeutics, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT06239480
- Locations
- 🇺🇸
Children's Hospital of Orange County, Irvine, California, United States
🇺🇸University of Utah Health, Salt Lake City, Utah, United States
🇺🇸Stanford University, Palo Alto, California, United States
A Study Evaluating the Safety and Pharmacokinetics of QTORIN Rapamycin 3.9% Anhydrous Gel in the Treatment of Adults With Pachyonychia Congenita
- First Posted Date
- 2022-12-09
- Last Posted Date
- 2022-12-09
- Lead Sponsor
- Palvella Therapeutics, Inc.
- Target Recruit Count
- 45
- Registration Number
- NCT05643872
- Locations
- 🇺🇸
Minnesota Clinical Study Center, New Brighton, Minnesota, United States
A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Pachyonychia Congenita
- Conditions
- Pachyonychia Congenita
- Interventions
- Drug: Vehicle
- First Posted Date
- 2022-01-06
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- Palvella Therapeutics, Inc.
- Target Recruit Count
- 87
- Registration Number
- NCT05180708
- Locations
- 🇺🇸
Oregon Health and Sciences University, Portland, Oregon, United States
🇺🇸Stanford University, Palo Alto, California, United States
🇺🇸Park Avenue Dermatology, Orange Park, Florida, United States
Study Evaluating the Safety and Efficacy of PTX-022 (QTORIN Sirolimus) in the Treatment of Microcystic Lymphatic Malformations
- First Posted Date
- 2021-09-20
- Last Posted Date
- 2025-01-17
- Lead Sponsor
- Palvella Therapeutics, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT05050149
- Locations
- 🇺🇸
Arkansas Children's Hospital, Little Rock, Arkansas, United States
🇺🇸Children's Hospital of Pennsylvania (CHOP), Philadelphia, Pennsylvania, United States
🇺🇸Minnesota Clinical Study Center, Fridley, Minnesota, United States
CODY: A Study Evaluating The Safety And Efficacy Of QTORIN 3.9% Sirolimus Topical Gel For The Prevention Of Basal Cell Carcinomas (BCCs) In Patients With Gorlin Syndrome
- Conditions
- BCCs in Gorlin Syndrome Patients
- Interventions
- Drug: Vehicle comparator
- First Posted Date
- 2021-05-19
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- Palvella Therapeutics, Inc.
- Target Recruit Count
- 73
- Registration Number
- NCT04893486
- Locations
- 🇺🇸
DermResearch Inc, Austin, Texas, United States
🇺🇸Mayo Clinic, Scottsdale, Arizona, United States
🇺🇸Virginia Clinical Research, Inc., Norfolk, Virginia, United States
VALO-2: Study Evaluating the Safety and Efficacy of PTX022 in the Treatment of Adults With Pachyonychia Congenita
- First Posted Date
- 2020-08-20
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- Palvella Therapeutics, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT04520750
- Locations
- 🇺🇸
Arizona Research Center, Phoenix, Arizona, United States
🇺🇸Minnesota Clinical Study Center, Fridley, Minnesota, United States
🇺🇸Stanford University, Palo Alto, California, United States
Phase 2/3 Study Evaluating the Safety and Efficacy of PTX-022 in Treatment of Adults With Pachyonychia Congenita
- First Posted Date
- 2019-04-18
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- Palvella Therapeutics, Inc.
- Target Recruit Count
- 73
- Registration Number
- NCT03920228
- Locations
- 🇺🇸
International Dermatology Research, Miami, Florida, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
🇺🇸Arizona Research Center, Phoenix, Arizona, United States